The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-14. Anything still debated is marked as such rather than presented as settled.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
=== Extraction === Lactobacillic acid can be isolated from the lipids of bacteria, as used by the working group during the discovery. First, hydrolysis (saponification) of the phospholipids or triglycerides is carried out, releasing the fatty acid bound as an ester. Since other fatty acids are present in addition to lactobacillic acid, separation is then carried out using urea extraction crystallization or column chromatography. The fractional crystallization process can also be used.
Vincent Marks (10 June 1930 – 6 November 2023) was an English pathologist and clinical biochemist known for his works on studying insulin and hypoglycemia. His contributions to medical science include simplifying low blood glucose testing, introducing insulin radioimmunoassay, and advancing diabetes research. Marks played an important role in high-profile medico-legal cases, notably providing expert testimony that helped acquit Danish-born British socialite Claus von Bülow in 1985, a case that was the basis of the Oscar-winning movie Reversal of Fortune (1990). Marks was also a nutritionist who studied intestinal hormones and coined the term "muesli belt malnutrition", referring to parents feeding their children what is considered extremely healthy foods, but, in the process depriving them of essential fats.
To provide a deeper scientific foundation for MD students, Einstein hosts the five-year Clinical Research Training Program (CRTP). The CRTP confers a Master of Science and requires an additional year of courses on clinical research methods. Students may also graduate with distinction in research for their medical degree. With Yeshiva's Benjamin N. Cardozo School of Law, Einstein offers both a certificate and Master of Science in Bioethics. The program covers clinical bioethics consultation, healthcare ethics policy, and human subject research. Einstein also offers MD students a joint Master of Public Health degree with the City University of New York (CUNY). This Einstein-CUNY MD-MPH program lasts five years.
=== Environmental and health concerns === Fluoroalkanes are generally inert and non-toxic. Fluoroalkanes are not ozone depleting, as they contain no chlorine or bromine atoms, and they are sometimes used as replacements for ozone-depleting chemicals. The term fluorocarbon is used rather loosely to include any chemical containing fluorine and carbon, including chlorofluorocarbons, which are ozone depleting. Perfluoroalkanes used in medical procedures are rapidly excreted from the body, primarily via expiration with the rate of excretion as a function of the vapour pressure; the half-life for octafluoropropane is less than 2 minutes, compared to about a week for perfluorodecalin.
=== Alcohols === Alcohols generally have weak molecular ion peaks due to the strong electronegativity of oxygen. “Alpha” cleavage is common due to the resonance stabilization. The largest alkyl group will be lost.
Sources: en.wikipedia.org
2,5-DMA is a low-potency serotonin 5-HT2A receptor partial agonist, with an affinity (Ki) of 2,502 nM, an EC50Tooltip half-maximal effective concentration of 160 to 3,548 nM (depending on the signaling cascade and study), and an EmaxTooltip maximal efficacy of 66 to 109%. It has also been assessed at several other receptors. In a much earlier study, its affinities (Ki) were 1,020 nM at the serotonin 5-HT1 receptor and 5,200 nM at the serotonin 5-HT2 receptor. The drug does not appear to bind to the monoamine transporters, at least at the assessed concentrations (up to 7,000 nM). It was inactive at the human trace amine-associated receptor 1 (TAAR1). 2,5-DMA shows dramatically reduced potency as a serotonin 5-HT2A receptor agonist compared to the DOx drugs, such as 2,5-dimethoxy-4-methylamphetamine (DOM). 2,5-DMA produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. However, it produces a very weak head-twitch response compared to other structurally related psychedelics like DOM, DOET, DOPR, and even DOBU. In addition, it is less potent in comparison. 2,5-DMA substitutes for DOM in rodent drug discrimination tests, albeit with dramatically lower potency than other DOx drugs. It also substitutes for 5-MeO-DMT in rodent drug discrimination tests. These findings suggesting that 2,5-DMA might produce weak hallucinogenic effects at sufficiently high doses. 2,5-DMA shows no substitution for dextroamphetamine in drug discrimination tests, suggesting that it lacks psychostimulant- or amphetamine-like effects, at least in rodents.
Consuming 75% of production, the primary use for strontium was in glass for colour television cathode-ray tubes, where it prevented X-ray emission. This application for strontium has been declining because CRTs are being replaced by other display methods. This decline has a significant influence on the mining and refining of strontium. All parts of the CRT must absorb X-rays. In the neck and the funnel of the tube, lead glass is used for this purpose, but this type of glass shows a browning effect due to the interaction of the X-rays with the glass. Therefore, the front panel is made from a different glass mixture with strontium and barium to absorb the X-rays. The average values for the glass mixture determined for a recycling study in 2005 is 8.5% strontium oxide and 10% barium oxide. Because strontium is so similar to calcium, it is incorporated in the bone. All four stable isotopes are incorporated, in roughly the same proportions they are found in nature. However, the actual distribution of the isotopes tends to vary greatly from one geographical location to another. Thus, analyzing the bone of an individual can help determine the region it came from. This approach helps to identify the ancient migration patterns and the origin of commingled human remains in battlefield burial sites. 87Sr/86Sr ratios are commonly used to determine the likely provenance areas of sediment in natural systems, especially in marine and fluvial environments.
==== Mast cell activation syndrome ==== Mast cell activation syndrome (MCAS) is a type of immune disorder and a subcategory of MCAD. MCAS is not considered a subtype of mastocytosis. MCAS likely includes multiple disorders with varying etiologies that are characterized by severe, acute, recurrent over-activation and degranulation of mast cells, marked by a transient increase in MC-derived mediators such as tryptase or histamine. Suggested causes of abnormal activation include changes in MC activation threshold, abnormal expression of receptors and mediators, environmental tissue changes affecting mediators, and regulatory gene mutations. Consensus diagnostic criteria for MCAS have been proposed, but as of 2022, diagnostic criteria for MCAS were not established by either the WHO 5th edition or ICC. Appropriate usage of the term MCAS and its diagnosis in patients continue to be debated. Three criteria are considered a standard for an MCAS diagnosis: a clinical criterion (severe, episodic MC activation symptoms in 2 or more organ systems); a laboratory criterion (detection of a substantial transient increase in a marker of MC activation such as tryptase, accompanying activation events); and a response criterion (control of symptoms with MC stabilizers or inhibitors of MC mediators). Since many clinical conditions can display symptoms similar to those resulting from MC activation, caution is recommended in the diagnosis of MCAS. It is essential to confirm that symptoms derive from MC activation and mediator release, not other mechanisms.
Thomas Edison began serious research into developing a practical incandescent lamp in 1878. Edison filed his first patent application for "Improvement in Electric Lights" on 14 October 1878. After many experiments, first with carbon in the early 1880s and then with platinum and other metals, in the end Edison returned to a carbon filament. The first successful test was on 22 October 1879, and lasted 13.5 hours. Edison continued to improve this design and by 4 November 1879, filed for a US patent for an electric lamp using "a carbon filament or strip coiled and connected ... to platina contact wires." Although the patent described several ways of creating the carbon filament including using "cotton and linen thread, wood splints, papers coiled in various ways," Edison and his team later discovered that a carbonized Japanese bamboo filament could last more than 1200 hours. In 1880, the Oregon Railroad and Navigation Company steamer, Columbia, became the first application for Edison's incandescent electric lamps (it was also the first ship to use a dynamo). Albon Man, a New York lawyer, started Electro-Dynamic Light Company in 1878 to exploit his patents and those of William Sawyer. Weeks later the United States Electric Lighting Company was organized. This company made their first commercial installation of incandescent lamps in the fall of 1880, at the Mercantile Safe Deposit Company in New York City, about six months after the Edison incandescent lamps had been installed on the Columbia. Hiram S. Maxim was the chief engineer at the United States Electric Lighting Company.
Materials science is also used by forensic engineers and failure analysts to understand why and how critical components fail, which helps prevent dangerous and costly accidents in areas such as aviation.
Sources: en.wikipedia.org
Some singers can isolate some of those harmonics in a way that is perceived as singing in more than one pitch at the same time—a technique called overtone singing or throat singing such as in the tradition of Tuvan throat singing.
=== Pharmacodynamics === Thiobuscaline shows affinity for the serotonin 5-HT2A receptor (Ki = 602 nM). It is a potent near-full agonist of the serotonin 5-HT2A and 5-HT2C receptors and to a much lesser extent a moderate-efficacy partial agonist of the serotonin 5-HT2B receptor, with EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) values of 3.86 nM (114%) at the serotonin 5-HT2A receptor, 89.6 nM (55.7%) at the serotonin 5-HT2B receptor, and 8.86 nM (95.9%) at the serotonin 5-HT2C receptor. Conversely, it was inactive as an agonist of the serotonin 5-HT1A receptor. The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.
Honey is collected from wild bee colonies or from domesticated beehives. On average, a hive will produce about 29 kilograms (65 lb) of honey per year. Wild bee nests are sometimes located by following a honeyguide bird. To safely collect honey from a hive, beekeepers typically pacify the bees using a bee smoker. The smoke triggers a feeding instinct (an attempt to save the resources of the hive from a possible fire), making them less aggressive, and obscures the pheromones the bees use to communicate. The honeycomb is removed from the hive and the honey may be extracted from it either by crushing or by using a honey extractor. The honey is then usually filtered to remove beeswax and other debris. Before the invention of removable frames, bee colonies were often sacrificed to conduct the harvest. The harvester would take all the available honey and replace the entire colony the next spring. Since the invention of removable frames, the principles of husbandry led most beekeepers to ensure that their bees have enough stores to survive the winter, either by leaving some honey in the beehive or by providing the colony with a honey substitute such as sugar water or crystalline sugar (often in the form of a "candyboard"). The amount of food necessary to survive the winter depends on the variety of bees and on the length and severity of local winters. Many animal species are attracted to wild or domestic sources of honey.
Ingestion of semen offers nominal nutritional value, but has been recorded for social and interpersonal purposes, with some religious or cultural traditions, incorporating it as a practice. It is a common element of oral sex in sexual relationships, and is a common act in pornography, with a number of different kinds of practices depicted.
== Reactions == The cycle comprises three enzyme-catalysed reactions. The first stage is the deamination of the purine nucleotide adenosine monophosphate (AMP) to form inosine monophosphate (IMP), catalysed by the enzyme AMP deaminase:
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.